Brief: Merus Announces Petosemtamab In Previously Treated Head And Neck Squamous Cell Carcinoma Abstract Selected For Plenary Session Oral Presentation At The Aacr Annual Meeting 2023
14/03/2023 22:51
March 14 (Reuters) - Merus NV MRUS.O :
* MERUS ANNOUNCES PETOSEMTAMAB IN PREVIOUSLY TREATED HEAD
AND NECK
SQUAMOUS CELL CARCINOMA ABSTRACT SELECTED FOR PLENARY SESSION
ORAL PRESENTATION AT THE AACR ANNUAL MEETING 2023
Source text for Eikon: ID:nGNXblj4GK
Further company coverage: MRUS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Merus NV
See all newsNASDAQ RESUMED AT 09:00 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 09:00 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
Brief: Merus And Halozyme enter global collaboration and license agreement to develop subcutaneous formulation Of Petosemtamab